PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Intestinal Research10.5217/ir.2016.14.2.1522016142152Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's diseaseKai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinsonhttp://www.irjournal.org/upload/pdf/ir-14-152.pdf
Yearbook of Gastroenterology10.1016/s0739-5930(08)70100-420072007120Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM TrialG.R. Lichtensteinhttps://api.elsevier.com/content/article/PII:S0739593008701004?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0739593008701004?httpAccept=text/plain
Digestive and Liver Disease10.1016/s1590-8658(09)60332-7200941S126INDUCTION AND MAINTENANCE OF CLINICAL RESPONSE AND REMISSION WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH INFLAMMATORY OR FISTULISING CROHN'S DISEASE: A REFERRAL CENTER EXPERIENCE OF COMPASSIONATE USEF. Mocciaro, D. Scimeca, S. Renna, A. Orlando, M. Cottonehttps://api.elsevier.com/content/article/PII:S1590865809603327?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1590865809603327?httpAccept=text/plain
Gastroenterology10.1053/j.gastro.2011.11.00620121421e31Exam 2: Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stoppedhttps://api.elsevier.com/content/article/PII:S0016508511015678?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508511015678?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(12)62172-620121425S-565Su2084 Efficacy of Certolizumab Pegol Induction and Maintenance Therapy in Patients With Crohn's Disease Not in Remission Following Active or Placebo InductionWilliam J. Sandborn, Ziad H. Younes, Bosny Pierre-Louis, Geert R. D'Haenshttps://api.elsevier.com/content/article/PII:S0016508512621726?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508512621726?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(14)61374-320141465S-382Su1126 In Patients With Crohn's Disease, Concomitant Enteral Nutrition Reduces the Loss of Response to Adalimumab Maintenance TherapyNaoki Yoshimura, Takaaki Kawaguchi, Minako Sako, Abbi Saniabadi, Masakazu Takazoehttps://api.elsevier.com/content/article/PII:S0016508514613743?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508514613743?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(16)31456-120161504S419Sa1968 Post-Induction Adalimumab Drug Levels Predict Clinical and Laboratory Remission at Week 24 in Patients With Crohn's DiseaseEran Zittan, Orlaith Kelly, Boyko Kabakchiev, Geoffrey C. Nguyen, Kenneth Croitoru, A. Hillary Steinhart, Mark S. Silverberghttps://api.elsevier.com/content/article/PII:S0016508516314561?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508516314561?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(14)61375-520141465S-382Su1127 In Patients With Crohn's Disease, Timing of Switching From Infliximab Maintenance Therapy to Adalimumab Affects Patients' PrognosisKen Takeuchi, Akihiro Yamada, Yasuo Suzukihttps://api.elsevier.com/content/article/PII:S0016508514613755?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508514613755?httpAccept=text/plain
Nature Reviews Gastroenterology & Hepatology10.1038/ncpgasthep1350200963129-129Adalimumab maintenance therapy improves quality of life in patients with Crohn's diseasehttp://www.nature.com/articles/ncpgasthep1350.pdf, http://www.nature.com/articles/ncpgasthep1350, http://www.nature.com/articles/ncpgasthep1350.pdf
Gastroenterology10.1016/s0016-5085(10)62167-120101385S-468-S-469T1012 Long-Term Maintenance of Clinical Remission With Reduced Dosing Frequency of Adalimumab in Patients With Moderate to Severe Crohn's DiseaseRemo Panaccione, Jean-Frederic Colombel, William J. Sandborn, Anne Robinson, Jingdong Chao, Parvez Mulani, Paul F. Pollackhttps://api.elsevier.com/content/article/PII:S0016508510621671?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508510621671?httpAccept=text/plain